<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340071</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Neutralizing Antibodies against 10 SARS-CoV-2 Variants at Two Years Post-COVISHIELD Vaccination with Special Reference to Omicron Subvariants and Booster Administration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1039</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091039</ELocationID><Abstract><AbstractText>To study the durability of neutralizing antibodies (NAbs) against ten SARS-CoV-2 variants among COVISHIELD vaccine recipients from Pune, India, 184 vaccinee samples with (pre-positives) or without (pre-negatives) prior antibody positivity were evaluated. To estimate NAb levels, a validated ten-plex MSD ACE2 neutralization assay was used. NAbs against Alpha, Beta, Delta, and Omicron/subvariants were assessed at 1 month (PD2-1) and 6 months (PD2-6) post-vaccination, post-booster dose, and 2 years (2Y) post-vaccination. In pre-negatives, the seropositivity declined from PD2-1 to PD2-6 for all variants (Omicron variants: 14-54% to 0%; non-Omicron variants: 66-100% to 8-44%). In pre-positives, the decline in seropositivity from PD2-1 to PD2-6 was seen only for Omicron variants (14-39%). At PD2-6, a significant reduction in NAb levels was observed in all vaccinees against all the variants. Irrespective of prior exposure, the diminished anti-variant antibody levels at PD2-6 increased significantly following the administration of the booster. In conclusion, the COVISHIELD vaccine booster dose did provide cross-neutralizing antibodies against broad-range SARS-CoV-2 variants with improved durability up to [16 (15-18)] months post-booster dose and two years post-vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Rajashree</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2367-4513</Identifier><AffiliationInfo><Affiliation>Department of Translational Virology, Interactive Research School for Health Affairs, Bharati Vidyapeeth (Deemed to be) University, Pune 411043, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palkar</LastName><ForeName>Sonali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Bharati Vidyapeeth Medical College, Bharati Vidyapeeth (Deemed to be) University, Pune 411043, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Akhileshchandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1836-1990</Identifier><AffiliationInfo><Affiliation>Department of Translational Virology, Interactive Research School for Health Affairs, Bharati Vidyapeeth (Deemed to be) University, Pune 411043, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arankalle</LastName><ForeName>Vidya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Translational Virology, Interactive Research School for Health Affairs, Bharati Vidyapeeth (Deemed to be) University, Pune 411043, Maharashtra, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BT/CS0006/CS/02/20</GrantID><Agency>Department of Biotechnology- Biotechnology Industry Research Assistance Council (DBT-BIRAC), India, under MISSION COVID SURAKSHA</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MSD</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">omicron</Keyword><Keyword MajorTopicYN="N">two-year follow-up</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340071</ArticleId><ArticleId IdType="pmc">PMC11435521</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091039</ArticleId><ArticleId IdType="pii">vaccines12091039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fontanet A., Autran B., Lina B., Kieny M.P., Karim S.S.A., Sridhar D. SARS-CoV-2 Variants and Ending the COVID-19 Pandemic. Lancet. 2021;397:952–954. doi: 10.1016/S0140-6736(21)00370-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00370-6</ArticleId><ArticleId IdType="pmc">PMC7906631</ArticleId><ArticleId IdType="pubmed">33581803</ArticleId></ArticleIdList></Reference><Reference><Citation>Arankalle V., Kulkarni-Munje A., Kulkarni R., Palkar S., Patil R., Oswal J., Lalwani S., Mishra A.C. Immunogenicity of Two COVID-19 Vaccines Used in India: An Observational Cohort Study in Health Care Workers from a Tertiary Care Hospital. Front. Immunol. 2022;13:928501. doi: 10.3389/fimmu.2022.928501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.928501</ArticleId><ArticleId IdType="pmc">PMC9540493</ArticleId><ArticleId IdType="pubmed">36211366</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil R., Palkar S., Mishra A., Patil R., Arankalle V. Variable Neutralizing Antibody Responses to 10 SARS-CoV-2 Variants in Natural Infection with Wild- Type (B.1) Virus, Kappa (B.1.617.1), and Delta (B.1.617.2) Variants and COVISHIELD Vaccine Immunization in India: Utility of the MSD Platform. Front. Immunol. 2023;14:1181991. doi: 10.3389/fimmu.2023.1181991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1181991</ArticleId><ArticleId IdType="pmc">PMC10277512</ArticleId><ArticleId IdType="pubmed">37342350</ArticleId></ArticleIdList></Reference><Reference><Citation>Haritay S., Patil R., Maldar A., Kumar A., Reddy V., Oswal D., Tahashildar M.A., Kolakar A., Kabbur S., Prasad J.B., et al. Waning of Antibody Response Among Vaccinees Who Received Two Doses of Covishield Vaccine. J. Glob. Infect. Dis. 2023;15:19–22. doi: 10.4103/jgid.jgid_128_22.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jgid.jgid_128_22</ArticleId><ArticleId IdType="pmc">PMC10118211</ArticleId><ArticleId IdType="pubmed">37090141</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., Moir M., Everatt J., Giovanetti M., Scheepers C., Wilkinson E., Subramoney K., Makatini Z., Moyo S., Amoako D.G., et al. Emergence of SARS-CoV-2 Omicron Lineages BA.4 and BA.5 in South Africa. Nat. Med. 2022;28:1785–1790. doi: 10.1038/s41591-022-01911-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01911-2</ArticleId><ArticleId IdType="pmc">PMC9499863</ArticleId><ArticleId IdType="pubmed">35760080</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Starr T.N., Gilchuk P., Zost S.J., Binshtein E., Loes A.N., Hilton S.K., Huddleston J., Eguia R., Crawford K.H.D., et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition. Cell Host Microbe. 2021;29:44. doi: 10.1016/j.chom.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J., et al. SARS-CoV-2 Variants, Spike Mutations and Immune Escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim S.S.A., Karim Q.A. Omicron SARS-CoV-2 Variant: A New Chapter in the COVID-19 Pandemic. Lancet. 2021;398:2126–2128. doi: 10.1016/S0140-6736(21)02758-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02758-6</ArticleId><ArticleId IdType="pmc">PMC8640673</ArticleId><ArticleId IdType="pubmed">34871545</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordelia F., Kirsebom M., Andrews N., Sachdeva R., Stowe J., Ramsay M., Lopez Bernal J. Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta Variants in England. Nat. Commun. 2022;386:1532–1546. doi: 10.1038/s41467-022-35168-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35168-7</ArticleId><ArticleId IdType="pmc">PMC9744366</ArticleId><ArticleId IdType="pubmed">36509743</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen H., Strengert M., Maaß H., Ynga Durand M.A., Katzmarzyk M., Kessel B., Harries M., Rand U., Abassi L., Kim Y., et al. Diminished Neutralization Responses towards SARS-CoV-2 Omicron VoC after MRNA or Vector-Based COVID-19 Vaccinations. Sci. Rep. 2022;12:19858. doi: 10.1038/s41598-022-22552-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22552-y</ArticleId><ArticleId IdType="pmc">PMC9673895</ArticleId><ArticleId IdType="pubmed">36400804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudjaritruk T., Mueangmo O., Saheng J., Winichakoon P., Salee P., Wongjak W., Chaito T., Praparattanapan J., Nuket K., Solai N., et al. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations. Vaccines. 2023;11:564. doi: 10.3390/vaccines11030564.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030564</ArticleId><ArticleId IdType="pmc">PMC10051392</ArticleId><ArticleId IdType="pubmed">36992147</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa Clemens S.A., Weckx L., Clemens R., Almeida Mendes A.V., Ramos Souza A., Silveira M.B.V., da Guarda S.N.F., de Nobrega M.M., de Moraes Pinto M.I., Gonzalez I.G.S., et al. Heterologous versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, Non-Inferiority, Single Blind, Randomised Study. Lancet. 2022;399:521–529. doi: 10.1016/S0140-6736(22)00094-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00094-0</ArticleId><ArticleId IdType="pmc">PMC8782575</ArticleId><ArticleId IdType="pubmed">35074136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose W., Raju R., Babji S., George A., Madhavan R., Leander Xavier J.V., David Chelladurai J.S., Nikitha O.S., Deborah A.A., Vijayakumar S., et al. Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 NCoV-19 (COVISHIELDTM) and BBV152 (COVAXIN®): A Non-Inferiority Phase 4, Participant and Observer-Blinded, Randomised Study. Lancet Reg. Health. 2023;12:100141. doi: 10.1016/j.lansea.2023.100141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2023.100141</ArticleId><ArticleId IdType="pmc">PMC9870748</ArticleId><ArticleId IdType="pubmed">36712811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren S.-Y., Wang W.-B., Gao R.-D., Zhou A.-M. Omicron Variant (B.1.1.529) of SARS-CoV-2: Mutation, Infectivity, Transmission, and Vaccine Resistance. World J. Clin. Cases. 2022;10:1–11. doi: 10.12998/wjcc.v10.i1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i1.1</ArticleId><ArticleId IdType="pmc">PMC8727245</ArticleId><ArticleId IdType="pubmed">35071500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. Where Did “weird” Omicron Come From? Science. 2021;374:1179. doi: 10.1126/science.acx9738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.acx9738</ArticleId><ArticleId IdType="pubmed">34855502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.B., Ma Y.B., Lei Z.H., Zhang X.F., Li J., Li S.S., Dong Z.Y., Liang Y., Li Q.M., Su J.G. Identification of Key Mutations Responsible for the Enhancement of Receptor-Binding Affinity and Immune Escape of SARS-CoV-2 Omicron Variant. J. Mol. Graph. Model. 2023;124:108540. doi: 10.1016/j.jmgm.2023.108540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2023.108540</ArticleId><ArticleId IdType="pmc">PMC10254043</ArticleId><ArticleId IdType="pubmed">37352723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Xu Y., Jian F., Song W., Yisimayi A., Wang P., Wang J., Liu J., Yu L., et al. Fast Evolution of SARS-CoV-2 BA.2.86 to JN.1 under Heavy Immune Pressure. Lancet Infect. Dis. 2024;24:e70–e72. doi: 10.1016/S1473-3099(23)00744-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Miyakawa K., Ohtake N., Yamaoka Y., Yajima S., Yamazaki E., Shimada T., Goto A., Nakajima H., Ryo A. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine. 2022;40:2652–2655. doi: 10.1016/j.vaccine.2022.03.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.057</ArticleId><ArticleId IdType="pmc">PMC8960126</ArticleId><ArticleId IdType="pubmed">35370020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet B., Chabrolles H., Archimbaud C., Brebion A., Cosme J., Dutheil F., Lambert C., Junda M., Mirand A., Ollier A., et al. Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. Front. Immunol. 2022;13:842912. doi: 10.3389/fimmu.2022.842912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.842912</ArticleId><ArticleId IdType="pmc">PMC8926062</ArticleId><ArticleId IdType="pubmed">35309363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>